Q1 concall summary
India growing at 15 to 16% ex covid
US will be flat this yr and low single digit at best
Europe likely to continue at 15% for next 2 to 3 yr
Row markets performing well and likely to continue at current run rate, brazil at breakeven
API will grow with more capcity coming upstream, demand is steady ( from gls concall)
Overall guidance of 6 to 8% for the year
Ebidta for the year likely at 19 %
Munroe likely to be remediated and operational by q4, no new fililing from munroe as of now
12 launches expected in US and 25 in india,
Debt likely to be pared down further
Capex at 700 cr, 40 cr of write off expected of covid drugs
1 outlicensing deals expected in this fy
Ichnos 2 proof of concept (1342 & 1442) expected this yr and isb 2001 human trials expected
Capital raise in ichnos still being targeted in this fy,
Ryaltris likely to be 100 to 150 mn drug in 3yr.my guess it will do approx 200 cr this yr, 600 by next yr once china and US also approves and 1000 cr by 3rd yr.
Apart from flovent one more pmdi likely to be commercialised by fy25.
Manpower costs will be at normal levels.
US had both pricing issues as well as supply chain issues. At least supply chain will be better from q2
Fda queries for india baddi, aurangabad etc have been responded.
| Subscribe To Our Free Newsletter |
